StudyFinder
PEPN2111 - A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma
Status: Recruiting
This study is testing a drug called CBL0137 in children and young people with certain cancers that have come back or have not responded to treatment, including solid tumors, brain and spinal cord tumors, and lymphoma. We want to learn what dose can be given safely, what side effects it may cause, and how well it may work against these cancers. What we learn may help guide future treatment options for children and young people with these cancers.
Sex: Male or Female
Age Group: Not specified
Inclusion Criteria:
• ages 1 through 21 years
• have a solid tumor, brain or spinal cord tumor, or lymphoma that has come back or has not responded to treatment
• have a cancer for which there is no known curative treatment
• have recovered from the major side effects of previous cancer treatment
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:
• are pregnant or breastfeeding
• are currently receiving another study drug or other cancer treatment
• have an uncontrolled infection
• have previously received a solid organ transplant
• see link to clinicaltrials.gov for complete exclusion criteria
Interventions:
Procedure: Biospecimen Collection, Procedure: Bone Marrow Aspirate, Procedure: Bone Marrow Biopsy, Procedure: Echocardiography Test, Drug: FACT Complex-targeting Curaxin CBL0137
Conditions:
Cancer, Cancer
Keywords:
Cancer, Gliomas, Brain Cancer, Recurrent Lymphoma
Study Contact: Allison Fullenkamp - fulle631@umn.edu
Principal Investigator: Robin Williams
Phase: PHASE1
IRB Number: SITE00001450
See this study on ClinicalTrials.gov